Cargando…
Systems-level biomarkers identification and drug repositioning in colorectal cancer
Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299930/ https://www.ncbi.nlm.nih.gov/pubmed/34322194 http://dx.doi.org/10.4251/wjgo.v13.i7.638 |
_version_ | 1783726358202941440 |
---|---|
author | Beklen, Hande Yildirim, Esra Kori, Medi Turanli, Beste Arga, Kazim Yalcin |
author_facet | Beklen, Hande Yildirim, Esra Kori, Medi Turanli, Beste Arga, Kazim Yalcin |
author_sort | Beklen, Hande |
collection | PubMed |
description | Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limited number of biomarkers have been translated into routine clinical practice to predict risk, prognosis and response to treatment. In the last decades, systems biology approaches at the omics level have gained importance. Over the years, several biomarkers for CRC have been discovered in terms of disease diagnosis and prognosis. On the other hand, a few drugs are being developed and used in clinics for the treatment of CRC. However, the development of new drugs is very costly and time-consuming as the research and development takes about 10 years and more than $1 billion. Therefore, drug repositioning (DR) could save time and money by establishing new indications for existing drugs. In this review, we aim to provide an overview of biomarkers for the diagnosis and prognosis of CRC from the systems biology perspective and insights into DR approaches for the prevention or treatment of CRC. |
format | Online Article Text |
id | pubmed-8299930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-82999302021-07-27 Systems-level biomarkers identification and drug repositioning in colorectal cancer Beklen, Hande Yildirim, Esra Kori, Medi Turanli, Beste Arga, Kazim Yalcin World J Gastrointest Oncol Review Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limited number of biomarkers have been translated into routine clinical practice to predict risk, prognosis and response to treatment. In the last decades, systems biology approaches at the omics level have gained importance. Over the years, several biomarkers for CRC have been discovered in terms of disease diagnosis and prognosis. On the other hand, a few drugs are being developed and used in clinics for the treatment of CRC. However, the development of new drugs is very costly and time-consuming as the research and development takes about 10 years and more than $1 billion. Therefore, drug repositioning (DR) could save time and money by establishing new indications for existing drugs. In this review, we aim to provide an overview of biomarkers for the diagnosis and prognosis of CRC from the systems biology perspective and insights into DR approaches for the prevention or treatment of CRC. Baishideng Publishing Group Inc 2021-07-15 2021-07-15 /pmc/articles/PMC8299930/ /pubmed/34322194 http://dx.doi.org/10.4251/wjgo.v13.i7.638 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Beklen, Hande Yildirim, Esra Kori, Medi Turanli, Beste Arga, Kazim Yalcin Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title | Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title_full | Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title_fullStr | Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title_full_unstemmed | Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title_short | Systems-level biomarkers identification and drug repositioning in colorectal cancer |
title_sort | systems-level biomarkers identification and drug repositioning in colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299930/ https://www.ncbi.nlm.nih.gov/pubmed/34322194 http://dx.doi.org/10.4251/wjgo.v13.i7.638 |
work_keys_str_mv | AT beklenhande systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer AT yildirimesra systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer AT korimedi systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer AT turanlibeste systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer AT argakazimyalcin systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer |